![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. HTA-Newsletter 40: p. 2.
Preview |
PDF (HTA-Newsletter 40)
- Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
127kB |
Official URL: http://hw.oeaw.ac.at/ita/hta-newsletter?frames=yes
| Item Type: | HTA Newsletter Item |
|---|---|
| Keywords: | Avastin, bevacizumab, monoclonal antibody, metastatic colorectal cancer (CRC), carcinoma of the colon or the rectum, first-line treatment, drug therapy, combination therapy, FOLFOX, irinotecan, risks, costs |
| Subjects: | QW Microbiology. Immunology WI Digestive system > WI 400-560 Intestines |
| Related URLs: | |
| References: | 1. EMEA 2005: Bevacizumab. URL: http://www.emea.eu.int/humandocs/PDFs/ EPAR/avastin/17199204de1.pdf. 2. Arznei-Telegramm 2005: Angiogenesehemmstoff-Bevacizumab (Avastin) bei kolorektalem Karzinom. URL: http://www.arzneitelegramm.de. 3. NHSC/GB 2004: Bevacizumab (Avastin) for first-line treatment of metastatic colorectal cancer – horizon scanning review. URL: http://pcpoh.bham.ac.uk/ publichealth/horizon/PDF_files/2004reports/Bevacizumab.pdf. |
| Language: | German |
| Number: | 40 |
| Deposited on: | 25 Feb 2008 19:28 |
| Last Modified: | 15 Jul 2020 17:36 |
Repository Staff Only: item control page